{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T17:47:29Z","timestamp":1783446449331,"version":"3.55.0"},"reference-count":54,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2014,4,1]],"date-time":"2014-04-01T00:00:00Z","timestamp":1396310400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Behavioural Brain Research"],"published-print":{"date-parts":[[2014,4]]},"DOI":"10.1016\/j.bbr.2014.01.017","type":"journal-article","created":{"date-parts":[[2014,1,27]],"date-time":"2014-01-27T21:07:29Z","timestamp":1390856849000},"page":"158-168","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"special_numbering":"C","title":["Intranasal administration of alpha-synuclein aggregates: a Parkinson's disease model with behavioral and neurochemical correlates"],"prefix":"10.1016","volume":"263","author":[{"given":"Marina A.","family":"Gruden","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatiana V.","family":"Davydova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor B.","family":"Narkevich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina G.","family":"Fomina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vladimir S.","family":"Kudrin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ludmilla A.","family":"Morozova-Roche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert D.E.","family":"Sewell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbr.2014.01.017_bib0005","doi-asserted-by":"crossref","first-page":"507","DOI":"10.2174\/138920308785915218","article-title":"Alpha-synuclein misfolding and neurodegenerative diseases","volume":"9","author":"Uversky","year":"2008","journal-title":"Curr. Protein Pept. Sci."},{"key":"10.1016\/j.bbr.2014.01.017_bib0010","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1007\/s13361-013-0676-z","article-title":"Binding of dopamine to alpha-synuclein is mediated by specific conformational states","volume":"24","author":"Illes-Toth","year":"2013","journal-title":"J. Am. Soc. Mass Spectrom."},{"key":"10.1016\/j.bbr.2014.01.017_bib0015","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/1478-811X-11-34","article-title":"Complexity of dopamine metabolism","volume":"11","author":"Meiser","year":"2013","journal-title":"Cell Commun. Signal."},{"key":"10.1016\/j.bbr.2014.01.017_bib0020","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1007\/s11064-009-9986-8","article-title":"Modulation of alpha-synuclein aggregation by dopamine: a review","volume":"34","author":"Leong","year":"2009","journal-title":"Neurochem. Res."},{"key":"10.1016\/j.bbr.2014.01.017_bib0025","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.jneuroim.2010.12.001","article-title":"Immunoprotection against toxic biomarkers is retained during Parkinson's disease progression","volume":"233","author":"Gruden","year":"2011","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.bbr.2014.01.017_bib0030","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.plipres.2010.05.004","article-title":"Alpha-synuclein, lipids and Parkinson's disease","volume":"49","author":"Ruiperez","year":"2010","journal-title":"Prog. Lipid Res."},{"key":"10.1016\/j.bbr.2014.01.017_bib0035","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1007\/s00401-012-0963-y","article-title":"Nigrostriatal overabundance of \u03b1-synuclein leads to decreased vesicle density and deficits in dopamine release that correlate with reduced motor activity","volume":"123","author":"Gaugler","year":"2012","journal-title":"Acta Neuropathol."},{"issue":"5","key":"10.1016\/j.bbr.2014.01.017_bib0040","doi-asserted-by":"crossref","first-page":"e9312","DOI":"10.1371\/journal.pone.0009312","article-title":"Alpha-synuclein disrupted dopamine homeostasis leads to dopaminergic neuron degeneration in Caenorhabditis elegans","volume":"19","author":"Cao","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.bbr.2014.01.017_bib0045","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/nrn983","article-title":"Pathogenesis of Parkinson's disease: dopamine, vesicles and \u03b1-synuclein","volume":"3","author":"Lotharius","year":"2002","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.bbr.2014.01.017_bib0050","doi-asserted-by":"crossref","first-page":"149","DOI":"10.4236\/jbpc.2012.32017","article-title":"Demonstration of three dopamine molecules bound to \u03b1-synuclein: implication of oligomerization at the initial stage","volume":"3","author":"Shimotakahara","year":"2012","journal-title":"J. Biophys. Chem."},{"key":"10.1016\/j.bbr.2014.01.017_bib0055","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fncel.2013.00081","article-title":"Dopamine prevents lipid peroxidation-induced accumulation of toxic \u03b1-synuclein oligomers by preserving autophagy-lysosomal function","volume":"7","author":"Jiang","year":"2013","journal-title":"Front. Cell Neurosci."},{"key":"10.1016\/j.bbr.2014.01.017_bib0060","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1159\/000341400","article-title":"Correlation between protective immunity to \u03b1-synuclein aggregates, oxidative stress and inflammation","volume":"19","author":"Gruden","year":"2012","journal-title":"Neuroimmunomodulation"},{"key":"10.1016\/j.bbr.2014.01.017_bib0065","doi-asserted-by":"crossref","first-page":"e18513","DOI":"10.1371\/journal.pone.0018513","article-title":"\u03b1-Synuclein reactive antibodies as diagnostic biomarkers in blood sera of Parkinson's disease patients","volume":"6","author":"Yanamandra","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.bbr.2014.01.017_bib0070","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1007\/978-1-61779-968-6_34","article-title":"Nanobodies as structural probes of protein misfolding and fibril formation","volume":"911","author":"De Genst","year":"2012","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.bbr.2014.01.017_bib0075","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.bbr.2013.01.011","article-title":"Nasal inoculation with \u03b1-synuclein aggregates evokes rigidity, locomotor deficits and immunity to such misfolded species as well as dopamine","volume":"243","author":"Gruden","year":"2013","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.bbr.2014.01.017_bib0080","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1038\/nprot.2006.342","article-title":"Protocol for the MPTP mouse model of Parkinson's disease","volume":"2","author":"Jackson-Lewis","year":"2007","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.bbr.2014.01.017_bib0085","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/S0166-4328(01)00309-6","article-title":"Behavioral phenotyping of the MPTP mouse model of Parkinson's disease","volume":"125","author":"Sedelis","year":"2001","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.bbr.2014.01.017_bib0090","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1006\/exnr.2002.8021","article-title":"Detection of behavioural impairments correlated to neurochemical deficits in mice treated with moderate doses of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine","volume":"178","author":"Tillerson","year":"2002","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.bbr.2014.01.017_bib0095","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/S0928-4680(96)00160-5","article-title":"Effects of fibroblast growth factors on MPTP-induced parkinsonian syndrome in mice","volume":"4","author":"Kryzhanovsky","year":"1997","journal-title":"Pathophysiology"},{"key":"10.1016\/j.bbr.2014.01.017_bib0100","first-page":"219","article-title":"Some observations on the effects of two enantiomers of two benzomorphan narcotic antagonists and atropine on analgesia, tremor and hypothermia produced by oxotremorine","volume":"256","author":"Ben-Sreti","year":"1982","journal-title":"Arch. Int. Pharmacodyn. Ther."},{"key":"10.1016\/j.bbr.2014.01.017_bib0105","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1038\/3311","article-title":"Accelerated in vitro fibril formation by a mutant alpha-synuclein linked to early-onset Parkinson disease","volume":"4","author":"Conway","year":"1998","journal-title":"Nat. Med."},{"key":"10.1016\/j.bbr.2014.01.017_bib0110","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S0022-2836(02)00775-1","article-title":"Dependence of alpha-synuclein aggregate morphology on solution conditions","volume":"322","author":"Hoyer","year":"2002","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.bbr.2014.01.017_bib0115","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1006\/jsbi.2000.4264","article-title":"Amyloid fibril formation and seeding by wild-type human lysozyme and its disease-related mutational variants","volume":"130","author":"Morozova-Roche","year":"2000","journal-title":"J. Struct. Biol."},{"key":"10.1016\/j.bbr.2014.01.017_bib0120","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1002\/pro.5560020312","article-title":"Thioflavine T interaction with synthetic Alzheimer's disease beta-amyloid peptides: detection of amyloid aggregation in solution","volume":"2","author":"LeVine","year":"1993","journal-title":"Protein Sci."},{"key":"10.1016\/j.bbr.2014.01.017_bib0125","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/S0022-2836(03)00551-5","article-title":"Amyloid protofilaments from the calcium-binding protein equine lysozyme: formation of ring and linear structures depends on pH and metal ion concentration","volume":"330","author":"Malisauskas","year":"2003","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.bbr.2014.01.017_bib0130","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.neuroscience.2011.03.007","article-title":"Modeling of preclinical and clinical stages of Parkinson's disease in mice","volume":"181","author":"Ugrumov","year":"2011","journal-title":"Neuroscience"},{"key":"10.1016\/j.bbr.2014.01.017_bib0135","doi-asserted-by":"crossref","first-page":"483","DOI":"10.2174\/138920309789351921","article-title":"Biophysics of Parkinson's disease: structure and aggregation of alpha-synuclein","volume":"10","author":"Uversky","year":"2009","journal-title":"Curr. Protein Pept. Sci."},{"key":"10.1016\/j.bbr.2014.01.017_bib0140","doi-asserted-by":"crossref","first-page":"249","DOI":"10.3233\/JPD-012138","article-title":"Loss of functional alpha-synuclein: a toxic event in Parkinson's disease?","volume":"2","author":"Kanaan","year":"2012","journal-title":"J. Parkinsons Dis."},{"key":"10.1016\/j.bbr.2014.01.017_bib0145","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1111\/j.1460-9568.2008.06346.x","article-title":"Olfactory deficits in mice overexpressing human wild type alpha-synuclein","volume":"28","author":"Fleming","year":"2008","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.bbr.2014.01.017_bib0150","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1111\/j.1365-2990.2007.00874.x","article-title":"Parkinson's disease: a dual-hit hypothesis","volume":"33","author":"Hawkes","year":"2007","journal-title":"Neuropathol. Appl. Neurobiol."},{"key":"10.1016\/j.bbr.2014.01.017_bib0155","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1007\/s12640-013-9401-8","article-title":"Evaluation of nigrostriatal neurodegeneration and neuroinflammation following repeated intranasal 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) administration in mice, an experimental model of Parkinson's disease","volume":"25","author":"Trist\u00e3o","year":"2014","journal-title":"Neurotox. Res."},{"key":"10.1016\/j.bbr.2014.01.017_bib0160","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/S0197-4580(02)00065-9","article-title":"Staging of brain pathology related to sporadic Parkinson's disease","volume":"24","author":"Braak","year":"2003","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.bbr.2014.01.017_bib0165","doi-asserted-by":"crossref","first-page":"2276","DOI":"10.1007\/s00415-011-6084-z","article-title":"Vagus nerve somatosensory evoked potentials in Parkinson's disease","volume":"258","author":"Polak","year":"2011","journal-title":"J. Neurol."},{"key":"10.1016\/j.bbr.2014.01.017_bib0170","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1016\/S1734-1140(12)70933-7","article-title":"Chronic impairment of the vagus nerve function leads to inhibition of dopamine but not serotonin neurons in rat brain structures","volume":"64","author":"Ziomber","year":"2012","journal-title":"Pharmacol. Rep."},{"key":"10.1016\/j.bbr.2014.01.017_bib0175","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1146\/annurev.cellbio.042308.113313","article-title":"\u03b1-Synuclein: membrane interactions and toxicity in Parkinson's disease","volume":"26","author":"Auluck","year":"2010","journal-title":"Annu. Rev. Cell Dev. Biol."},{"key":"10.1016\/j.bbr.2014.01.017_bib0180","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1385\/JMN:23:1-2:023","article-title":"Interactions among alpha-synuclein, dopamine, and biomembranes: some clues for understanding neurodegeneration in Parkinson's disease","volume":"23","author":"Rochet","year":"2004","journal-title":"J. Mol. Neurosci."},{"key":"10.1016\/j.bbr.2014.01.017_bib0185","doi-asserted-by":"crossref","first-page":"482","DOI":"10.2174\/187152710791556177","article-title":"Alpha-synuclein and MPTP-generated rodent models of Parkinson's disease and the study of extracellular striatal dopamine dynamics: a microdialysis approach","volume":"9","author":"Bazzu","year":"2010","journal-title":"CNS Neurol. Disord. Drug Targets"},{"key":"10.1016\/j.bbr.2014.01.017_bib0190","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1007\/s12640-010-9232-9","article-title":"Behavioral, neurochemical, and electrophysiological changes in an early spontaneous mouse model of nigrostriatal degeneration","volume":"20","author":"Sgad\u00f2","year":"2011","journal-title":"Neurotox. Res."},{"key":"10.1016\/j.bbr.2014.01.017_bib0195","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/s00401-006-0096-2","article-title":"Interaction of alpha-synuclein and dopamine metabolites in the pathogenesis of Parkinson's disease: a case for the selective vulnerability of the substantia nigra","volume":"112","author":"Galvin","year":"2006","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.bbr.2014.01.017_bib0200","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s00401-007-0303-9","article-title":"Aggregation of alpha-synuclein by DOPAL, the monoamine oxidase metabolite of dopamine","volume":"115","author":"Burke","year":"2008","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.bbr.2014.01.017_bib0205","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.nbd.2012.05.012","article-title":"Dysregulated dopamine storage increases the vulnerability to \u03b1-synuclein in nigral neurons","volume":"47","author":"Ulusoy","year":"2012","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.bbr.2014.01.017_bib0210","doi-asserted-by":"crossref","first-page":"e55068","DOI":"10.1371\/journal.pone.0055068","article-title":"Dopamine-mediated oxidation of methionine 127 in \u03b1-synuclein causes cytotoxicity and oligomerization of \u03b1-synuclein","volume":"8","author":"Nakaso","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.bbr.2014.01.017_bib0215","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.jmb.2009.03.053","article-title":"At low concentrations, 3,4-dihydroxyphenylacetic acid (DOPAC) binds non-covalently to alpha-synuclein and prevents its fibrillation","volume":"388","author":"Zhou","year":"2009","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.bbr.2014.01.017_bib0220","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1111\/j.1471-4159.2009.06072.x","article-title":"Differences between subacute and chronic MPTP mice models: investigation of dopaminergic neuronal degeneration and alpha-synuclein inclusions","volume":"109","author":"Gibrat","year":"2009","journal-title":"J. Neurochem."},{"key":"10.1016\/j.bbr.2014.01.017_bib0225","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/S0304-3940(03)00097-1","article-title":"Attenuation of dopamine transporter activity by alpha-synuclein","volume":"340","author":"Wersinger","year":"2003","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.bbr.2014.01.017_bib0230","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1016\/j.febslet.2011.03.009","article-title":"Synuclein modulation of monoamine transporters","volume":"585","author":"Oaks","year":"2011","journal-title":"FEBS Lett."},{"key":"10.1016\/j.bbr.2014.01.017_bib0235","doi-asserted-by":"crossref","first-page":"3213","DOI":"10.1073\/pnas.1200575109","article-title":"Impaired neurotransmission caused by overexpression of \u03b1-synuclein in nigral dopamine neurons","volume":"109","author":"Lundblad","year":"2012","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.bbr.2014.01.017_bib0240","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1007\/s12640-011-9281-8","article-title":"Intranasal administration of neurotoxicants in animals: support for the olfactory vector hypothesis of Parkinson's disease","volume":"21","author":"Prediger","year":"2012","journal-title":"Neurotox. Res."},{"key":"10.1016\/j.bbr.2014.01.017_bib0245","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/j.neuro.2004.05.002","article-title":"Mice lacking alpha-synuclein have an attenuated loss of striatal dopamine following prolonged chronic MPTP administration","volume":"25","author":"Drolet","year":"2004","journal-title":"Neurotoxicology"},{"key":"10.1016\/j.bbr.2014.01.017_bib0250","doi-asserted-by":"crossref","first-page":"20051","DOI":"10.1073\/pnas.0908005106","article-title":"Exogenous alpha-synuclein fibrils seed the formation of Lewy body-like intracellular inclusions in cultured cells","volume":"106","author":"Luk","year":"2009","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.bbr.2014.01.017_bib0255","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.expneurol.2012.05.022","article-title":"Do \u03b1-synuclein vector injections provide a better model of Parkinson's disease than the classic 6-hydroxydopamine model?","volume":"237","author":"Lindgren","year":"2012","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.bbr.2014.01.017_bib0260","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1002\/syn.20484","article-title":"Intranasal dopamine application increases dopaminergic activity in the neostriatum and nucleus accumbens and enhances motor activity in the open field","volume":"62","author":"de Souza Silva","year":"2008","journal-title":"Synapse"},{"key":"10.1016\/j.bbr.2014.01.017_bib0265","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.euroneuro.2009.02.005","article-title":"Intranasal application of dopamine reduces activity and improves attention in Naples high excitability rats that feature the mesocortical variant of ADHD","volume":"19","author":"Ruocco","year":"2009","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.bbr.2014.01.017_bib0270","doi-asserted-by":"crossref","first-page":"4194","DOI":"10.1073\/pnas.1100976108","article-title":"In vivo demonstration that alpha-synuclein oligomers are toxic","volume":"108","author":"Winner","year":"2011","journal-title":"Proc. Natl. Acad. Sci. U.S.A."}],"container-title":["Behavioural Brain Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016643281400031X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016643281400031X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,8,14]],"date-time":"2020-08-14T18:31:45Z","timestamp":1597429905000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S016643281400031X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,4]]},"references-count":54,"alternative-id":["S016643281400031X"],"URL":"https:\/\/doi.org\/10.1016\/j.bbr.2014.01.017","relation":{},"ISSN":["0166-4328"],"issn-type":[{"value":"0166-4328","type":"print"}],"subject":[],"published":{"date-parts":[[2014,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Intranasal administration of alpha-synuclein aggregates: a Parkinson's disease model with behavioral and neurochemical correlates","name":"articletitle","label":"Article Title"},{"value":"Behavioural Brain Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbr.2014.01.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}